Literature DB >> 28253990

Mitochondrial Perturbation in Alzheimer's Disease and Diabetes.

F Akhter1, D Chen1, S F Yan1, S S Yan2.   

Abstract

Mitochondria are well-known cellular organelles that play a vital role in cellular bioenergetics, heme biosynthesis, thermogenesis, calcium homeostasis, lipid catabolism, and other metabolic activities. Given the extensive role of mitochondria in cell function, mitochondrial dysfunction plays a part in many diseases, including diabetes and Alzheimer's disease (AD). In most cases, there is overwhelming evidence that impaired mitochondrial function is a causative factor in these diseases. Studying mitochondrial function in diseased cells vs healthy cells may reveal the modified mechanisms and molecular components involved in specific disease states. In this chapter, we provide a concise overview of the major recent findings on mitochondrial abnormalities and their link to synaptic dysfunction relevant to neurodegeneration and cognitive decline in AD and diabetes. Our increased understanding of the role of mitochondrial perturbation indicates that the development of specific small molecules targeting aberrant mitochondrial function could provide therapeutic benefits for the brain in combating aging-related dementia and neurodegenerative diseases by powering up brain energy and improving synaptic function and transmission.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Diabetes; Mitochondrial dysfunction; Neuronal toxicity; Synaptic degeneration aging

Mesh:

Substances:

Year:  2017        PMID: 28253990      PMCID: PMC5896572          DOI: 10.1016/bs.pmbts.2016.12.019

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  128 in total

1.  The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae.

Authors:  Camilla A Hansson Petersen; Nyosha Alikhani; Homira Behbahani; Birgitta Wiehager; Pavel F Pavlov; Irina Alafuzoff; Ville Leinonen; Akira Ito; Bengt Winblad; Elzbieta Glaser; Maria Ankarcrona
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

2.  Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction.

Authors:  Nicola Origlia; Massimo Righi; Simona Capsoni; Antonino Cattaneo; Fang Fang; David M Stern; John Xi Chen; Ann Marie Schmidt; Ottavio Arancio; Shi Du Yan; Luciano Domenici
Journal:  J Neurosci       Date:  2008-03-26       Impact factor: 6.167

3.  Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension.

Authors:  Peizhong Mao; Maria Manczak; Marcus J Calkins; Quang Truong; Tejaswini P Reddy; Arubala P Reddy; Ulziibat Shirendeb; Herng-Hsiang Lo; Peter S Rabinovitch; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2012-04-05       Impact factor: 6.150

4.  An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease.

Authors:  S D Yan; J Fu; C Soto; X Chen; H Zhu; F Al-Mohanna; K Collison; A Zhu; E Stern; T Saido; M Tohyama; S Ogawa; A Roher; D Stern
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

5.  Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice.

Authors:  Lauren M Billings; Salvatore Oddo; Kim N Green; James L McGaugh; Frank M LaFerla
Journal:  Neuron       Date:  2005-03-03       Impact factor: 17.173

6.  Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment.

Authors:  G J Biessels; A Kamal; I J Urban; B M Spruijt; D W Erkelens; W H Gispen
Journal:  Brain Res       Date:  1998-07-27       Impact factor: 3.252

Review 7.  The mitochondrial permeability transition pore: a molecular target for amyotrophic lateral sclerosis therapy.

Authors:  Lee J Martin
Journal:  Biochim Biophys Acta       Date:  2009-08-03

8.  Mitochondrial dynamics modulate the expression of pro-inflammatory mediators in microglial cells.

Authors:  Junghyung Park; Hoonsung Choi; Ju-Sik Min; Sun-Ji Park; Jung-Hak Kim; Hyo-Jin Park; Bokyung Kim; Jung-Il Chae; Mijung Yim; Dong-Seok Lee
Journal:  J Neurochem       Date:  2013-07-29       Impact factor: 5.372

9.  Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease.

Authors:  P Fernández-Vizarra; A P Fernández; S Castro-Blanco; J Serrano; M L Bentura; R Martínez-Murillo; A Martínez; J Rodrigo
Journal:  Histol Histopathol       Date:  2004-07       Impact factor: 2.303

10.  Genetic deficiency of neuronal RAGE protects against AGE-induced synaptic injury.

Authors:  Hongju Zhang; Yongfu Wang; Shijun Yan; Fang Du; Long Wu; Shiqiang Yan; Shirley S Yan
Journal:  Cell Death Dis       Date:  2014-06-12       Impact factor: 8.469

View more
  17 in total

1.  The Cannabinoid Receptor Agonist WIN55,212-2 Ameliorates Hippocampal Neuronal Damage After Chronic Cerebral Hypoperfusion Possibly Through Inhibiting Oxidative Stress and ASK1-p38 Signaling.

Authors:  Da-Peng Wang; Qiao-Li Lv; Qi Lin; Kai Kang; Kai-Yan Jin; Jian Hai
Journal:  Neurotox Res       Date:  2019-12-05       Impact factor: 3.911

Review 2.  A tale of two systems: Lessons learned from female mid-life aging with implications for Alzheimer's prevention & treatment.

Authors:  Aarti Mishra; Yiwei Wang; Fei Yin; Francesca Vitali; Kathleen E Rodgers; Maira Soto; Lisa Mosconi; Tian Wang; Roberta D Brinton
Journal:  Ageing Res Rev       Date:  2021-12-17       Impact factor: 10.895

Review 3.  Saffron as a promising therapy for diabetes and Alzheimer's disease: mechanistic insights.

Authors:  Sarvin Sanaie; Saba Nikanfar; Zahra Yousefi Kalekhane; Akbar Azizi-Zeinalhajlou; Saeed Sadigh-Eteghad; Mostafa Araj-Khodaei; Mohammad Hossein Ayati; Sasan Andalib
Journal:  Metab Brain Dis       Date:  2022-08-20       Impact factor: 3.655

4.  Age-dependent accumulation of dicarbonyls and advanced glycation endproducts (AGEs) associates with mitochondrial stress.

Authors:  Firoz Akhter; Doris Chen; Asma Akhter; Shi Fang Yan; Shirley ShiDu Yan
Journal:  Free Radic Biol Med       Date:  2021-01-05       Impact factor: 7.376

Review 5.  Amyloid β and free heme: bloody new insights into the pathogenesis of Alzheimer's disease.

Authors:  Jörg Flemmig; Marcel Zámocký; A Alia
Journal:  Neural Regen Res       Date:  2018-07       Impact factor: 5.135

6.  Berberine Alleviates Amyloid β-Induced Mitochondrial Dysfunction and Synaptic Loss.

Authors:  Chunhui Zhao; Ping Su; Cui Lv; Limin Guo; Guoqiong Cao; Chunxia Qin; Wensheng Zhang
Journal:  Oxid Med Cell Longev       Date:  2019-05-02       Impact factor: 6.543

Review 7.  Biopharmaceutical Monotargeting versus 'Universal Targeting' of Late-Onset Alzheimer's Disease Using Mixtures of Pleiotropic Natural Compounds.

Authors:  Howard Friel
Journal:  J Alzheimers Dis Rep       Date:  2019-07-24

8.  The Effect of Adherence to Screening Guidelines on the Risk of Alzheimer's Disease in Elderly Individuals Newly Diagnosed With Type 2 Diabetes Mellitus.

Authors:  Arseniy P Yashkin; Igor Akushevich; Svetlana Ukraintseva; Anatoliy Yashin
Journal:  Gerontol Geriatr Med       Date:  2018-11-13

9.  Antidiabetic and Neuroprotective Effect of the N-Butanol Extract of Fragaria nilgerrensis Schlecht. in STZ-Induced Diabetic Mice.

Authors:  Liangcai Gao; Xinyi Wang; Zejie Lin; Ningning Song; Xinnan Liu; Xinxin Chi; Tiange Shao
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-04       Impact factor: 2.629

10.  Mitochondrial Dysfunction: A Common Hallmark Underlying Comorbidity between sIBM and Other Degenerative and Age-Related Diseases.

Authors:  Marc Catalán-García; Francesc Josep García-García; Pedro J Moreno-Lozano; Gema Alcarraz-Vizán; Adrià Tort-Merino; José César Milisenda; Judith Cantó-Santos; Tamara Barcos-Rodríguez; Francesc Cardellach; Albert Lladó; Anna Novials; Glòria Garrabou; Josep M Grau-Junyent
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.